Switching Between GLP-1 Medications

Switching between GLP-1 receptor agonists is a common clinical decision driven by efficacy, tolerability, insurance coverage, or supply availability. GLP-1 switches often cross molecular families: semaglutide and liraglutide are single-hormone GLP-1 agonists, while tirzepatide is a dual GIP/GLP-1 agonist with different receptor binding. There is no universal dose-equivalence table between these molecules, and a safe switch typically restarts at the new drug's lowest titration step. FDA prescribing information for each drug recommends gradual escalation to minimize gastrointestinal side effects, which may transiently worsen after a switch. The guides below cover the most common switch pathways — including dose considerations, GI-tolerability risk windows, and prior-authorization implications — with the caveat that all medication changes must be supervised by a prescribing clinician.